Stockscreener 앱 받기
18.51
5.89%
1.03
전일 마감가:
$17.48
열려 있는:
$17.53
하루 거래량:
505.27K
Relative Volume:
0.95
시가총액:
$502.63M
수익:
$157.75M
순이익/손실:
$-29.73M
주가수익비율:
-15.96
EPS:
-1.16
순현금흐름:
$-21.00M
1주 성능:
-4.98%
1개월 성능:
+27.39%
6개월 성능:
+4.16%
1년 성능:
-13.79%
1일 변동 폭
$17.39
$19.00
1주일 범위
$16.71
$19.69
52주 변동 폭
$8.04
$25.88
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
명칭
Arcturus Therapeutics Holdings Inc
전화
(858) 900-2660
주소
10628 SCIENCE CENTER DRIVE, SAN DIEGO, CA
ARCT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARCT
Arcturus Therapeutics Holdings Inc
|
18.51 | 486.34M | 157.75M | -29.73M | -21.00M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-28 | 개시 | Scotiabank | Sector Outperform |
| 2025-01-28 | 개시 | BTIG Research | Buy |
| 2024-08-12 | 개시 | Leerink Partners | Outperform |
| 2023-12-13 | 개시 | Canaccord Genuity | Buy |
| 2023-07-24 | 개시 | William Blair | Outperform |
| 2023-05-11 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2022-11-14 | 재개 | Wells Fargo | Overweight |
| 2022-11-10 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2022-11-03 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-11-02 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-08-10 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2022-07-19 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-05-11 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
| 2022-04-21 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-01-31 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2021-08-12 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2021-08-11 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-08-10 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2021-07-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-06-25 | 재개 | Goldman | Neutral |
| 2021-06-21 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2021-06-04 | 재개 | Robert W. Baird | Neutral |
| 2021-02-17 | 다운그레이드 | B. Riley Securities | Neutral → Sell |
| 2021-01-19 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-01-15 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-01-07 | 개시 | Wells Fargo | Overweight |
| 2020-12-29 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2020-12-29 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-12-29 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-12-29 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-12-23 | 다운그레이드 | ROTH Capital | Buy → Sell |
| 2020-12-08 | 재확인 | B. Riley Securities | Buy |
| 2020-12-07 | 재확인 | B. Riley Securities | Buy |
| 2020-10-26 | 개시 | Barclays | Overweight |
| 2020-10-06 | 개시 | Citigroup | Buy |
| 2020-08-26 | 개시 | Piper Sandler | Overweight |
| 2020-07-30 | 재개 | ROTH Capital | Buy |
| 2020-07-16 | 개시 | Raymond James | Outperform |
| 2020-07-13 | 개시 | B. Riley FBR | Buy |
| 2020-06-09 | 다운그레이드 | WBB Securities | Buy → Hold |
| 2020-02-11 | 개시 | Robert W. Baird | Outperform |
| 2020-02-07 | 개시 | Guggenheim | Buy |
| 2020-02-06 | 개시 | Guggenheim | Buy |
| 2019-04-05 | 개시 | H.C. Wainwright | Buy |
| 2018-09-20 | 업그레이드 | WBB Securities | Buy → Strong Buy |
| 2018-01-22 | 개시 | Chardan Capital Markets | Buy |
모두보기
Arcturus Therapeutics Holdings Inc 주식(ARCT)의 최신 뉴스
Is Arcturus Therapeutics Holdings Inc. the Top Chart Pick This Week2025 Key Lessons & AI Driven Price Forecasts - kangso.co.kr
Arcturus Therapeutics Holdings Inc. Added to High Probability Setup ListWeekly Stock Summary & Accurate Technical Buy Alerts - beatles.ru
Arcturus Therapeutics Stock Rises After Promising Mid-Stage Data for OTC Deficiency Treatment - MSN
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q2 2025 Earnings Call Transcript - MSN
Is Now a Good Time to Reenter Arcturus Therapeutics Holdings Inc.July 2025 Breakouts & Safe Capital Allocation Plans - beatles.ru
Arcturus Therapeutics (ARCT) Surges 29% on Intraday Frenzy: What’s Fueling the Biotech Breakout? - AInvest
Intapp Posts Better-Than-Expected Earnings, Joins… - inkl
Arcturus Therapeutics (NASDAQ:ARCT) Upgraded at Wall Street Zen - MarketBeat
Arcturus Therapeutics Receives Bullish Rating Amid Promising Cystic Fibrosis and COVID-19 Vaccine Progress - AInvest
Citi Raises Arcturus Therapeutics Price Target to $49, Keeps Buy Rating - AInvest
William Blair Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating - 富途牛牛
Mercury Systems Surges 24.6% After Reporting Better-Than-Expected Q4 Earnings, Green Dot, Arcturus Therapeutics, and Other Stocks Rise Amid US Market Gains - AInvest
Mercury Systems Posts Better-Than-Expected Earnings,… - inkl
Arcturus Therapeutics shares rise 29.68% intraday after positive interim Phase 2 data for ARCT-810. - AInvest
Real Messenger Corporation shares rise 28.05% intraday after Arcturus Therapeutics announced positive Phase 2 data for ARCT-810. - AInvest
Arcturus Therapeutics: Wells Fargo Maintains Overweight, PT Down to $42 from $45 - AInvest
Wells Fargo lowers Arcturus Therapeutics stock price target to $42 on model updates - Investing.com Canada
Arcturus Therapeutics shares rise 6.23% premarket after positive interim Phase 2 data for ARCT-810. - AInvest
Arcturus Therapeutics Announces Second Quarter 2025 Financial Update and Pipeline Progress - BioSpace
Arcturus Therapeutics Reports Q2 2025 Earnings and Pipeline Progress - TipRanks
Arcturus Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
Arcturus Therapeutics Holdings Inc earnings missed by $3.55, revenue fell short of estimates - Investing.com Nigeria
Arcturus Therapeutics Advances CF and OTC Programs, Plans Regulatory Meetings in 2026 - AInvest
Transcript : Arcturus Therapeutics Holdings Inc., Q2 2025 Earnings Call, Aug 11, 2025 - MarketScreener
Arcturus Tightens Its Belt As Analysts Stay Bullish - Finimize
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Arcturus Therapeutics: Q2 Earnings Snapshot - MarketScreener
Earnings call transcript: Arcturus Therapeutics Q2 2025 results miss expectations - Investing.com
Arcturus Therapeutics Holdings Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Arcturus Therapeutics Q2 net loss narrows - MarketScreener
Arcturus Therapeutics shares edge higher despite earnings miss in Q2 - Investing.com India
Arcturus Therapeutics shares edge higher despite earnings miss in Q2 By Investing.com - Investing.com Australia
Arcturus Therapeutics Q2 2025 Financial Update - TradingView
Short interest data insights for Arcturus Therapeutics Holdings Inc.Historical Market Behavior and Trend Summary - Newser
Risk vs reward if holding onto Arcturus Therapeutics Holdings Inc.Swing Trade Timing with Daily Forecast - Newser
Multi factor analysis applied to Arcturus Therapeutics Holdings Inc.High Yield Signals with Entry Timing - Newser
Arcturus Therapeutics Q2 2025 Earnings Preview: Analysts Expect EPS of -$0.87, Revenue of $18.71M. - AInvest
Arcturus Therapeutics Holdings Inc expected to post a loss of 89 cents a shareEarnings Preview - TradingView
What To Expect From Arcturus Therapeutics Holdings Inc (ARCT) Q2 2025 Earnings - GuruFocus
Lipid Nanoparticles Market Industry Trends, Key Growth Drivers, Challenges, Future Opportunities, and Regulatory Landscape 2025-2034 - GlobeNewswire Inc.
Tango Therapeutics, Inc. (TNGX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Is Arcturus Therapeutics Holdings Inc. stock overvalued or undervaluedHigh-yield portfolio picks - Jammu Links News
What is the risk reward ratio of investing in Arcturus Therapeutics Holdings Inc. stockRapid return acceleration - Jammu Links News
How does Arcturus Therapeutics Holdings Inc. compare to its industry peersFree Risk Assessment Services - Jammu Links News
What are analysts’ price targets for Arcturus Therapeutics Holdings Inc. in the next 12 monthsBuild a winning investment portfolio - Jammu Links News
When is Arcturus Therapeutics Holdings Inc. stock expected to show significant growthDiscover breakthrough stocks before the crowd - Jammu Links News
Is Arcturus Therapeutics Holdings Inc. a growth stock or a value stockGet professional guidance for market timing - Jammu Links News
What catalysts could drive Arcturus Therapeutics Holdings Inc. stock higher in 2025Get alerts on high-potential stock breakouts - Jammu Links News
What drives Arcturus Therapeutics Holdings Inc. stock priceAchieve rapid financial growth with smart picks - Jammu Links News
What is Arcturus Therapeutics Holdings Inc. company’s growth strategyTremendous financial leverage - Jammu Links News
What are Arcturus Therapeutics Holdings Inc. company’s key revenue driversRapid return acceleration - Jammu Links News
Arcturus Therapeutics Holdings Inc (ARCT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.94%
1.72%
자본화:
|
볼륨(24시간):